Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
1999-11-13
2002-03-12
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094630, C435S212000, C435S215000, C435S217000
Reexamination Certificate
active
06355243
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field
The invention is related to thrombolytic therapy with the plasmin, specifically by local delivery of active plasmin proximal to or directly at the clot site. This therapeutic method is particularly applicable to the dissolution of clots wherever catheter directed delivery is feasible, particularly for example in distal limbs (e.g. arms and legs).
2. Background
Plasmin, the principle fibrinolytic enzyme in mammals, is a serine protease with trypsin-like specificity. It derives from the inactive precursor plasminogen which circulates in plasma at a concentration of ~1.5 &mgr;M. Plasminogen activators such as tPA or urokinase cleave a single-chain plasminogen molecule at the Arg
560
-Val
561
peptide bond, producing active plasmin. The resulting two chains of plasmin are held together by two interchain disulphide bridges. The light chain (25 kDa) carries the catalytic center and is homologous to trypsin and other serine proteases. The heavy chain (60 kDa) consists of five very homologous triple-loop structures called kringles. Some kringles contain the so called lysine-binding sites which are responsible for plasminogen/plasmin interaction with fibrin, á
2
-antiplasmin and other proteins.
In spite of the success of thrombolytic drugs such as tissue plasminogen activator (tPA), streptokinase and urokinase, various thrombotic disorders, including myocardial infarction, occlusive stroke, deep venous thrombosis and peripheral arterial disease, remain a serious clinical problem. It appears that the currently available thrombolytic agents have several important limitations. At best, TIMI flow 3 within 90 min is obtained in approximately 50% of patients, acute coronary reocclusion occurs in roughly 10% of patients, coronary recanalization requires on average 45 minutes or more, intracerebral bleedings occurs in 0.3% to 0.7% of patients, and the residual mortality is at least 50% of that without thrombolytic treatment. Therefore, it is not surprising that research in the area of thrombolytics has focused on improvement of the existing plasminogen activators and finding new ones in an attempt to improve their fibrin specificity and increase plasma half-life to allow bolus administration.
The focus of development has been new plasminogen activators and with the exception of novel plasminogen activator (nPA), they all exhibit better fibrin specificity. They preserve the circulating levels of fibrinogen, plasminogen, á
2
-antiplasmin, Factors VIII and V. Nevertheless, based on the results of Phase II clinical trials with TNK-tPA and nPA, the improved safety profile of the new plasminogen activators has not translated into the better clinical outcome following thrombolytic therapy. The percentage of moderate and major bleeding episodes, including intracranial hemorrhage and stroke, were comparable with original tPA. The clogged arteries were not opened earlier and the rate of re-occlusions remains unchanged. It appears that the only benefit these activators have is the prolonged plasma half-life and the possibility of bolus administration.
An abstract on the method of treatment provided herein was published in BLOOD, Journal of the American Society of Hematology, Nov. 15, 1998, Abstract 3400. The abstract disclosed the potential of active Plasmin as a thrombolytic agent with the shift in modern fibronolytic treatment from systemic to local delivery.
U.S. Pat. No. 5,288,489 assigned to Orion Therapeutic Systems, Inc. discloses a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of an intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels. This patent discloses the generation of plasmin from plasminogen just prior to its introduction into the body. The plasminogen is activated, or an plasmin inhibitor is removed, just prior to administration.
SUMMARY OF THE INVENTION
This invention relates to the discovery that thrombolytic therapy can be improved by the administration of active plasmin directly at or proximal to the site of a clot. Plasmin autodegrades and has not been available for therapeutic administration. This invention provides a method of preparing active plasmin for such direct administration. Plasmin is obtained by isolating plasminogen from Cohn Fraction II & II, activating the plasminogen obtained to plasmin and isolating the plasmin in an aqueous solution having a pH of less than about 4 to provide a stable formulation of plasmin. Plasminogen may be activated by using a plasminogen activator, such as urokinase, bound to an affinity resin column, preferably a urokinase-sepharose column. The active plasmin may then be captured on a benzamidine affinity resin, preferably a benzamidine-Sepharose column, and finally eluted with a low pH buffer. The eluted plasmin is formulated in an aqueous solution, acidified to a pH of less than about 4, preferably, about 3.7. The aqueous plasmin solution may be lyophilized and is substantially free of plasminogen activator. No extensive manipulation is required to administer this formulation. Proof is provided herein that this is a viable therapy compared to the current use of plasminogen activators that can cause extraneous bleeding along with dissolution of a clot.
REFERENCES:
patent: 3434929 (1969-03-01), Buck et al.
patent: 3950513 (1976-04-01), Jensen
patent: 4082612 (1978-04-01), Robbins et al.
patent: 4177262 (1979-12-01), Lormeau et al.
patent: 4361652 (1982-11-01), Uemura et al.
patent: 4361653 (1982-11-01), Watanabe et al.
patent: 4442213 (1984-04-01), Heber et al.
patent: 4446316 (1984-05-01), Chazov et al.
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: 4908204 (1990-03-01), Robinson et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5290692 (1994-03-01), Suzuki et al.
patent: 5304383 (1994-04-01), Eibl et al.
patent: 5328996 (1994-07-01), Boyle
patent: 5472692 (1995-12-01), Liu et al.
patent: 5776452 (1998-07-01), Eibl et al.
patent: 5879923 (1999-03-01), Yago et al.
patent: 6139819 (2000-10-01), Unger et al.
Ambrus, C., et al., “Insolubilized Activators of the Fibrinolysin System,”J. Med.vol. 3, pp. 270-281 (1972).
Amris, C.J., et al., “Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer,”Danish Medical Bulletin, vol. 11, No. 5; pp. 141-145 (1964).
Amris, C.J., et al., “Turnover and Distribution of131I-Labelled Procine Plasmin in Man and Dog,”Danish Medical Bulletin, vol. 11, No. 5; pp. 146-152 (1964).
Anlyan, W., et al., “Experiences with Fibrinolysin in Peripheral Vascular Occlusive Disease,”The American Journal of Cardiology, pp. 507-512 (1960).
Boucek, R., et al., “Segmental Perfusion of the Coronary Arteries with Fibrinolysin in Man Following a Myocardial Infarction,”Am. J. Cardiol.vol. 6; pp. 525-533 (1960).
Freitag, H., et al., “Lys-plasminogen as an Adjunct to Local Intra-arterial Fibrinolysis of Carotid Territory Stroke: Laboratory and Clinical Findings,”Neuroradiology, vol. 38; pp. 181-185 (1996).
Hedner, U., et al., “Effects of Porcine Plasmin on the Coagulation and Fibrinolytic Systems in Humans,”Blood, vol. 51, No. 1; pp. 157-164 (1978).
Kitamoto, Y., et al., “A Femoral Vein Catheter with Immobilized Urokinase (UKFC) as an Antithrombotic Blood Access,”Trans Am Soc Artif Intern Organs, vol. 33, pp. 136-139 (1987).
Larsen, V., “Fibrinolytic Enzyme in the Treatment of Patients with Cancer,”Danish Medical Bulletin, vol. 2; No. 5; pp. 137-140 (1964).
Larson, V., et al., “Fibrinolytic Treatment with Activator-Free Porcine Plasmin,”Scand. J. Clin. Invest.18 (Suppl. 89); pp. 34-73 (1966).
Moser, K., “Effects of Intravenous Administration of Fibrinolysin (Plasmin) in Man,”Circulation, vol. 20; pp. 42-55 (1959).
Sherry, S., “The Origin of Thrombolytic Therapy,”J. Am. Coll. Cardiol., vol. 14, No. 4; pp. 1085-1
Jesmok Gary J.
Landskroner Kyle A.
Novokhatny Valery V.
Taylor Kathryn K.
Zimmerman Thomas P.
Bayer Corporation
Flood Michele C.
Tate Christopher R.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Method of thrombolysis by local delivery of active plasmin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of thrombolysis by local delivery of active plasmin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of thrombolysis by local delivery of active plasmin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2823997